| 臺大學術典藏 |
2021-03-11T12:03:52Z |
Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy
|
Keng L.-T.;Shu C.-C.;Chen J.Y.P.;Liang S.-K.;Ching-Kai Lin;Chang L.-Y.;Chang C.-H.;Wang J.-Y.;Yu C.-J.;Lee L.-N.; Keng L.-T.; Shu C.-C.; Chen J.Y.P.; Liang S.-K.; CHING-KAI LIN; Chang L.-Y.; Chang C.-H.; Wang J.-Y.; Yu C.-J.; Lee L.-N. |
| 臺大學術典藏 |
2021-03-11T12:03:51Z |
Clinical characteristics of bacteraemia caused by Lactobacillus spp. and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2000-2014
|
Lee M.-R.; Tsai C.-J.; Liang S.-K.; CHING-KAI LIN; Huang Y.-T.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-03-11T08:34:25Z |
Bacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp. bolletii: Clinical features and susceptibilities of the isolates
|
Lee M.-R.;Jen-Chang Ko;Liang S.-K.;Lee S.-W.;Yen D.H.-T.;Hsueh P.-R.; MENG-RUI LEE; JEN-CHANG KO; SHENG-KAI LIANG; Lee S.-W.; Yen D.H.-T.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-03-11T08:34:22Z |
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
|
Pan C.-H.;Chang Y.-F.;Lee M.-S.;Wen B.-C.;Jen-Chang Ko;Liang S.-K.;Liang M.-C.; Pan C.-H.; Chang Y.-F.; Lee M.-S.; Wen B.-C.; JEN-CHANG KO; SHENG-KAI LIANG; Liang M.-C. |
| 臺大學術典藏 |
2021-03-11T08:34:21Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Keng L.-T.;Jen-Chang Ko;Shih J.-Y.; SHENG-KAI LIANG; Min-Shu Hsieh; MENG-RUI LEE; LI-TA KENG; JEN-CHANG KO; Jin-Yuan Shih |
| 臺大學術典藏 |
2021-03-11T08:34:19Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.;Lee M.-R.;Liao W.-Y.;Ho C.-C.;Jen-Chang Ko;Shih J.-Y.; SHENG-KAI LIANG; MENG-RUI LEE; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:34:18Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.;Jen-Chang Ko;Yang J.C.-H.;Shih J.-Y.; SHENG-KAI LIANG; JEN-CHANG KO; James Chih-Hsin Yang; Jin-Yuan Shih |
| 臺大學術典藏 |
2021-03-11T08:29:38Z |
Bacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp. bolletii: Clinical features and susceptibilities of the isolates
|
Lee M.-R.;Jen-Chang Ko;Liang S.-K.;Lee S.-W.;Yen D.H.-T.;Hsueh P.-R.; Lee M.-R.; JEN-CHANG KO; Liang S.-K.; Lee S.-W.; Yen D.H.-T.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-03-11T08:29:36Z |
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
|
Pan C.-H.; Chang Y.-F.; Lee M.-S.; Wen B.-C.; JEN-CHANG KO; Liang S.-K.; Liang M.-C. |
| 臺大學術典藏 |
2021-03-11T08:29:35Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:29:34Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:29:32Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.; JEN-CHANG KO; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:29:29Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T07:58:33Z |
Bacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp. bolletii: Clinical features and susceptibilities of the isolates
|
Lee M.-R.;Jen-Chang Ko;Liang S.-K.;Lee S.-W.;Yen D.H.-T.;Hsueh P.-R.; Lee M.-R.; JEN-CHANG KO; Liang S.-K.; Lee S.-W.; Yen D.H.-T.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-03-11T07:58:31Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T07:58:31Z |
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
|
Pan C.-H.; Chang Y.-F.; Lee M.-S.; Wen B.-C.; JEN-CHANG KO; Liang S.-K.; Liang M.-C. |
| 臺大學術典藏 |
2021-03-11T07:58:28Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T07:58:27Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang S.-K.; JEN-CHANG KO; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T07:58:24Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-02-05T07:26:14Z |
Performance assessment of the DR. TBDR/NTM IVD kit for direct detection of Mycobacterium tuberculosis isolates, including rifampin-resistant isolates, and nontuberculous mycobacteria
|
Lee M.-R.; Cheng A.; Huang Y.-T.; Liu C.-Y.; KUEI-PIN CHUNG; Wang H.-C.; Liang S.-K.; Liao C.-H.; Yu C.-J.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-02-05T07:26:10Z |
Significant clinical factors associated with long-term mortality in critical cancer patients requiring prolonged mechanical ventilation
|
Keng L.-T.;Kuei-Pin Chung;Lin S.-Y.;Liang S.-K.;Cheng J.-C.;Chen I.-C.;Chen Y.-F.;Chang H.-T.;Hsu C.-L.;Jerng J.-S.;Wang H.-C.;Kuo P.-H.;Wu H.-D.;Shih J.-Y.;Yu C.-J.; Keng L.-T.; KUEI-PIN CHUNG; Lin S.-Y.; Liang S.-K.; Cheng J.-C.; Chen I.-C.; Chen Y.-F.; Chang H.-T.; Hsu C.-L.; Jerng J.-S.; Wang H.-C.; Kuo P.-H.; Wu H.-D.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-01-08T02:56:50Z |
Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy
|
LI-TA KENG; Shu C.-C.; Chen J.Y.P.; Liang S.-K.; Lin C.-K.; Chang L.-Y.; Chang C.-H.; Wang J.-Y.; Yu C.-J.; Lee L.-N. |
| 臺大學術典藏 |
2021-01-08T02:56:48Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Li-Ta Keng;Ko J.-C.;Shih J.-Y.; Liang S.-K.; Hsieh M.-S.; Lee M.-R.; LI-TA KENG; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-01-08T02:56:47Z |
Bronchial atresia
|
Li-Ta Keng;Liang S.-K.; LI-TA KENG; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-01-08T02:56:46Z |
Significant clinical factors associated with long-term mortality in critical cancer patients requiring prolonged mechanical ventilation
|
Yen-Fu Chen; I-Chun Chen; Jui-Chen Cheng; SHENG-KAI LIANG; Shu-Yung Lin; Li-Ta Keng;Chung K.-P.;Lin S.-Y.;Liang S.-K.;Cheng J.-C.;Chen I.-C.;Chen Y.-F.;Chang H.-T.;Hsu C.-L.;Jerng J.-S.;Wang H.-C.;Kuo P.-H.;Wu H.-D.;Shih J.-Y.;Yu C.-J.; LI-TA KENG; Kuei-Pin Chung; Hou-Tai Chang; Chia-Lin Hsu; Jih-Shuin Jerng; Hao-Chien Wang; Ping-Hung Kuo; Huey-Dong Wu; Jin-Yuan Shih; Chong-Jen Yu |
